Professor Wu Xiaobing Invited to the China Women Physicians Conference and Elected as a Member of the Rare Disease Professional Committee

Recently, Genecradle Therapeutics' GC301 adeno-associated virus (AAV) injection for the treatment of late-onset Pompe disease (LOPD) has successfully completed the first intravenous dosing in a gene t

Recently, in the "13th China Innovation and Entrepreneurship Competition Beijing Regional Biomedical Industry Competition and the 9th Beijing Innovation and Entrepreneurship Biomedical and Artificial

On July 10, 2024, the Phase I/II clinical trial kick-off meeting for the treatment of type 3 spinal muscular atrophy (SMA) patients with GC101 adeno-associated virus injection, an AAV gene therapy dru

The Global Cell & Gene Therapy Summit 2024 (CGT Summit 2024) was held as scheduled in Boston, the United States from July 8 to 10, 2024. The summit brought together pharmaceutical companies and re

On the morning of June 17, 2024, the launch meeting of the "Single-arm, multicenter, open, intravenous Phase I/II clinical study on the safety and efficacy of GC301 adeno-associated virus injection in

June 8, 2024GeneCradle's 6th anniversarySix years of youth and vigorSix years of hard work and fruitful resultsSix years is the length of a historical mark.It records GeneCradle's pace of development,

Beijing GeneCradle Technology Co., Ltd. (hereinafter referred to as "GeneCradle") independently developed the first AAV intrathecal gene drug for the treatment of type 1 SMA in China, GC101 adeno-asso